Jo K Perry
Overview
Explore the profile of Jo K Perry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Gelb M, Tamshen K, Forsythe N, Ko J, Puente E, et al.
Biomacromolecules
. 2024 Oct;
25(12):7619-7629.
PMID: 39471281
Zwitterionic polymers have been found to be biocompatible alternatives to poly(ethylene glycol) (PEG) for conjugation to proteins. This work reports the site-selective conjugation of poly(caprolactone-carboxybetaine) (pCLZ) to human growth hormone...
2.
Ramzan F, Rong J, Roberts C, OSullivan J, Perry J, Taylor R, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273483
Globally, preterm birth (PTB) is a primary cause of mortality and morbidity in infants, with PTB rates increasing worldwide over the last two decades. Biomarkers for accurate early prediction of...
3.
Farrow S, Gokuladhas S, Schierding W, Pudjihartono M, Perry J, Cooper A, et al.
NPJ Parkinsons Dis
. 2024 Feb;
10(1):44.
PMID: 38413607
Genome wide association studies (GWAS) have identified a number of genomic loci that are associated with Parkinson's disease (PD) risk. However, the majority of these variants lie in non-coding regions,...
4.
Lu M, Buckley C, Wang Y, Langley R, Perry J
J Mol Endocrinol
. 2023 Oct;
72(1).
PMID: 37855323
Excess growth hormone (GH) has been implicated in multiple cancer types and there is increasing interest in the development of therapeutic inhibitors targeting GH-GH receptor (GHR) signalling. Here we describe...
5.
Wang Y, Kim M, Buckley C, Maynard H, Langley R, Perry J
Protein Sci
. 2023 Jul;
32(9):e4727.
PMID: 37428391
Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can...
6.
Wang Y, Jamieson S, Perry J
Endocr Relat Cancer
. 2023 Jun;
30(9).
PMID: 37310137
Decades of published research support a role for growth hormone (GH) in cancer. Accordingly, there is increasing interest in targeting GH in oncology, with GH antagonists exhibiting efficacy in xenograft...
7.
Jain L, Vickers M, Jacob B, Middleditch M, Chudakova D, Ganley A, et al.
J Cell Commun Signal
. 2023 Apr;
17(3):925-937.
PMID: 37043098
Growth hormone (GH) actions are mediated through binding to its cell-surface receptor, the GH receptor (GHR), with consequent activation of downstream signalling. However, nuclear GHR localisation has also been observed...
8.
Pudjihartono M, Perry J, Print C, OSullivan J, Schierding W
Clin Epigenetics
. 2022 Sep;
14(1):120.
PMID: 36171609
Background: There has been extensive scrutiny of cancer driving mutations within the exome (especially amino acid altering mutations) as these are more likely to have a clear impact on protein...
9.
Ho D, Nyaga D, Schierding W, Saffery R, Perry J, Taylor J, et al.
Commun Biol
. 2021 Sep;
4(1):1072.
PMID: 34521982
Type 1 diabetes (T1D) etiology is complex. We developed a machine learning approach that ranked the tissue-specific transcription regulatory effects for T1D SNPs and estimated their relative contributions to conversion...
10.
Wang Y, Langley R, Tamshen K, Harms J, Middleditch M, Maynard H, et al.
Biomacromolecules
. 2020 Dec;
22(2):299-308.
PMID: 33295758
Growth hormone (GH) has been implicated in cancer progression andis a potential target for anticancer therapy. Currently, pegvisomant is the only GH receptor (GHR) antagonist approved for clinical use. Pegvisomant...